Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1962 1
1963 1
1964 2
1965 1
1980 1
1981 4
1982 7
1983 6
1984 11
1985 5
1986 7
1987 12
1988 14
1989 13
1990 6
1991 16
1992 10
1993 20
1994 23
1995 16
1996 18
1997 13
1998 20
1999 37
2000 28
2001 35
2002 31
2003 51
2004 51
2005 51
2006 51
2007 65
2008 65
2009 72
2010 79
2011 70
2012 83
2013 78
2014 83
2015 49
2016 62
2017 70
2018 50
2019 60
2020 54
2021 43
2022 37
2023 33
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

1,429 results

Results by year

Filters applied: . Clear all
Page 1
Cnidarians are CLOCKing in.
Kwiatkowski ER, Emery P. Kwiatkowski ER, et al. Among authors: emery p. Elife. 2024 May 8;13:e98512. doi: 10.7554/eLife.98512. Elife. 2024. PMID: 38716806 Free PMC article.
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test.
Di Matteo A, Mankia K, Garcia-Montoya L, Sharrack S, Duquenne L, Nam JL, Mahler M, Emery P. Di Matteo A, et al. Among authors: emery p. RMD Open. 2024 Apr 10;10(2):e003927. doi: 10.1136/rmdopen-2023-003927. RMD Open. 2024. PMID: 38599655 Free PMC article.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Cope AP, et al. Among authors: emery p. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364839 Free article. Clinical Trial.
First-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding.
Drake LR, Wu Y, Naganawa M, Asch R, Zheng C, Najafzadeh S, Pracitto R, Lindemann M, Li S, Ropchan J, Labaree D, Emery PR, Dias M, Henry S, Nabulsi N, Matuskey D, Hillmer AT, Gallezot JD, Carson RE, Cai Z, Huang Y. Drake LR, et al. Among authors: emery pr. J Nucl Med. 2024 Feb 15;65(3):462-9. doi: 10.2967/jnumed.123.266470. Online ahead of print. J Nucl Med. 2024. PMID: 38360052
Clocks at sea: the genome-editing tide is rising.
Kwiatkowski ER, Rosenthal JJC, Emery P. Kwiatkowski ER, et al. Among authors: emery p. Trends Genet. 2024 May;40(5):387-397. doi: 10.1016/j.tig.2024.01.006. Epub 2024 Feb 8. Trends Genet. 2024. PMID: 38336520 Review.
1,429 results